Immunic (IMUX) Long-Term Debt Issuances (2024 - 2025)

Immunic (IMUX) reported Long-Term Debt Issuances of $55.9 million for Q4 2025, up 1081.39% sequentially from $4.7 million in Q2 2025.

Immunic (IMUX) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends

Immunic (IMUX) has 2 years of Long-Term Debt Issuances data on file, last reported at $55.9 million in Q4 2025.

For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $55.9 million; the trailing twelve-month figure through Dec 2025 stood at $60.7 million (changed N/A YoY), and the FY2025 full-year result was $60.7 million, changed N/A from the prior year.
Long-Term Debt Issuances rose to $55.9 million in Q4 2025, from $4.7 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $74.3 million in Q1 2024 to a low of -$74.3 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Immunic	11.03 Mn	11.03 Mn	-	-

Download Data